ID Biomedical announces the beginning of a U.S. phase I clinical trial for plague vaccine candidate

Share Name	Share Symbol	Market	Type
ID Biomedical - Common Shares (MM)	NASDAQ:IDBE	NASDAQ	Common Stock

ID Biomedical (NASDAQ:IDBE)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more ID Biomedical Charts.

ID Biomedical announces the beginning of a U.S. phase I clinical trial for plague vaccine candidate VANCOUVER, BC, Jan. 10 /PRNewswire-FirstCall/ -- ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today the beginning of a phase I clinical trial for a recombinant injectable plague vaccine candidate. The project is headed by DVC LLC, with ID Biomedical serving as the manufacturing development partner. ID Biomedical began its collaboration with DVC in 2003 for the development of a subunit plague vaccine; the three contracts awarded to IDB include analytic and process development, and manufacturing activities related to producing the vaccine under current Good Manufacturing Practices (GMP). DVC is the prime systems contractor for the Department of Defense Joint Vaccine Acquisition Program (JVAP). The open-label study will evaluate the safety, tolerability and immunogenicity of the vaccine candidate in healthy volunteers between the ages of 18 and 40. Testing is underway and will continue into 2005 at the University of Kentucky Chandler Medical Center in Lexington, Kentucky. The plague vaccine candidate is designed to provide protection against the plague bacterium Yersinia pestis, and was originally identified and developed by scientists working at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Their work involved the identification of suitable protein antigens and the initial research of the processes used to assess the performance of the vaccine. Further development of the processes to produce and test the vaccine, as well as GMP manufacturing of the candidate antigen, was performed by ID Biomedical. "We are delighted to participate in a project that has the potential to serve significant needs in the U.S. biodefense program. Our experience in subunit vaccine development, coupled with our proprietary manufacturing technology, has been critical to the initiation of this clinical trial. This project adds to our biodefense assets and is another positive step in the building of this business unit," said George Lowell, MD COL, USA (ret.), Chief Scientific Officer, Biodefense of ID Biomedical. About Plague The Plague is an infectious disease caused by the bacterium Yersinia Pestis. There have been over 150 recorded plague epidemics or pandemics. It is recognized as a major potential bioterrorism threat if it is spread in the air (aerosolized) because when the bacterium is inhaled into the lungs it causes an aggressive pneumonia that is nearly always fatal. Human to human infection occurs when a person with plague pneumonia coughs and spreads the bacteria into the air, which is then inhaled by others. Diagnosis of plague pneumonia is difficult because early symptoms are similar to the flu. There is currently no licensed plague vaccine in the United States. The development of plague vaccines is addressed in the NIH's National Institute of Allergy and Infectious Diseases' Strategic Plan for Biodefense Research. Plague vaccine development is one of six priority research areas intended to accelerate the creation of new products to combat bioterrorism. About DVC DVC LLC, a CSC company, is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines for the Department of Defense and civilian populations. As the prime systems contractor for the Joint Vaccine Acquisition Program, DVC engages the expertise of subcontractors, research centers and biologics development industry leaders. About ID Biomedical ID Biomedical is an integrated biotechnology company dedicated to the development of innovative vaccine products. It operates in research, development, manufacturing, sales and marketing from its facilities in Canada and in the United States. ID Biomedical is dedicated to becoming a premier vaccine company with significant marketed products worldwide and an extensive pipeline in both clinical and preclinical development. ID Biomedical has a leading position in the Canadian influenza market. It received a ten-year mandate from the Government of Canada in 2001 to assure a state of readiness in the case of an influenza pandemic and provide influenza vaccine for all Canadians in such an event. It also currently supplies approximately 75% of the Canadian government's influenza vaccine purchases. For further information on ID Biomedical, please visit the Company's website at http://www.idbiomedical.com/. The information in this news release contains so-called "forward-looking" statements. These include statements regarding ID Biomedical's expectations and plans relating to the closing of the loan transaction and the repurchase of the subscription receipts described herein, statements about ID Biomedical's expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "ID Biomedical believes", "management believes", and similar language. All forward-looking statements are based on ID Biomedical's current expectations and are subject to risks and uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the company's ability to successfully integrate the Shire vaccine business; (ii) the company's ability to successfully complete preclinical and clinical development of its products; (iii) the company's ability to manufacture its products; (iv) the seasonality of the flu-vaccine business and related fluctuations in the company's revenues from quarter to quarter; (v) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; (vi) the company's ability to enter into distribution agreements for its products, and to complete and maintain corporate alliances relating to the development and commercialization of its technology and products; (vii) market acceptance of its technologies and products; and (viii) the competitive environment and impact of technological change and other risks detailed in the company's filings with the Securities and Exchange Commission. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them. For further information, please contact: Investor Relations/Media - Dean Linden, (604) 431-9314, ; Michele Roy, (450) 978-6313, DATASOURCE: ID Biomedical Corporation CONTACT: Investor Relations/Media - Dean Linden, (604) 431-9314, ; Michele Roy, (450) 978-6313, ; To request a free copy of this organization's annual report, please go to http://www.newswire.ca/ and click on reports@cnw.

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

IDBE ID Biomedical - Common Shares (MM)